Anticipated $-0.07 EPS for Cytosorbents Corporation (CTSO) on May, 14

April 17, 2018 - By Andrea Pope

Cytosorbents Corporation (NASDAQ:CTSO) Corporate Logo
Big Money Sentiment increased to 2.89 in 2017 Q4. It has change of 1.62, from 2017Q3’s 1.27. The ratio is positive due to Cytosorbents Corporation positioning: 5 sold and 4 reduced. 12 funds bought positions and 14 increased positions. Investors holded 2.38 million in 2017Q3 but now own 2.91 million shares or 22.09% more.
Millennium Management Limited Liability Company holds 163,977 shs. Northern Trust accumulated 48,114 shs. California Pub Employees Retirement System invested in 0% or 46,100 shs. 17,689 are held by Alpine Ltd. Bluecrest Capital Mngmt holds 60,892 shs. Financial Bank Of America Corp De holds 0% or 5,000 shs in its capital. Susquehanna Grp Llp stated it has 61,909 shs. Pnc Group accumulated 0% or 15,000 shs. Commercial Bank Of Ny Mellon Corp has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Salem Counselors Inc holds 13,000 shs. Art Advisors Ltd reported 10,647 shs or 0% of all its holdings. Glg Prtn L P has 0.01% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 24,047 shs. Morgan Stanley has 8,056 shs. Moreover, Blackrock has 0% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 140,137 shs. Geode Management Llc has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO).

Cytosorbents Corporation had 5 sales and 0 insider buys since January 8, 2018. This’s net activity of $513,810.

Investors wait Cytosorbents Corporation (NASDAQ:CTSO)’s quarterly earnings on May, 14., Faxor reports. Analysts have anticipation on stock’s EPS of $-0.07. That’s down 40.00 % from last year’s $-0.05 EPS. After $-0.12 EPS report last quarter, Wall Street now forecasts -41.67 % EPS growth of Cytosorbents Corporation. On during the last trading session the stock decreased $0.15 or 1.85%, reaching $7.95.Cytosorbents Corporation has volume of 29,850 shares. Since April 17, 2017 CTSO has risen 28.83% and is uptrending. The stock outperformed the S&P 500 by 17.28%.

Cytosorbents Corporation (NASDAQ:CTSO) Ratings Coverage

In total 3 analysts cover Cytosorbents Corp (NASDAQ:CTSO). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:CTSO)’s analyst reports since November 6, 2017 according to StockzIntelligence Inc. On Friday, March 9 the firm has “Buy” rating by H.C. Wainwright given. On Thursday, March 8 the firm earned “Buy” rating by Cowen & Co. On Tuesday, January 9 the stock has “Buy” rating by H.C. Wainwright.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology.The firm is worth $234.30 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.Currently it has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Cytosorbents Corporation (NASDAQ:CTSO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: